Skin cryptococcosis in an immunocompromised renal-transplant recipient

Miglė Jarašūnienėa,b,∗, Emilija Šerpytienėa,b, Justina Mackevičiūtėc, Jonas Lauraitisa,b, Jūratė Grigaitienėa,b

a Vilnius University Hospital Santaros Klinikos, Centre of Dermatovenereology, Vilnius, Lithuania
b Vilnius University Faculty of Medicine, Clinic of Infectious Diseases and Dermatovenereology, Vilnius, Lithuania
c Vilnius University Faculty of Medicine, Lithuania

ARTICLE INFO
Keywords:
Cryptococcus spp
Cryptococcosis
Renal transplant

ABSTRACT
Immunosuppression after solid-organ transplantation can lead to opportunistic infections as cryptococcosis. A 69-year-old female, cadaveric renal-transplant recipient, manifested with ulcerative lesions on the 7th month of immunosuppression. Histological examination confirmed the diagnosis of cryptococcosis. Treatment with systemic and topical antifungal therapy for 7 months concluded in significant cutaneous improvement. This case presentation encourages high clinical suspicion of opportunistic pathogens such as Cryptococcus spp. and highlights the necessity of appropriate management.

1. Introduction
Cutaneous infectious complications are common in kidney transplant recipients because of a long term immunosuppression after transplantation. Consequently, opportunistic atypical pathogens as Cryptococcus spp., an encapsulated yeast found in soil, become dangerous. Cryptococcosis is an invasive fungal infection that has a worldwide distribution. For this reason it is important to maintain high suspicion for more rarely encountered pathogens and to master appropriate management in immunocompromised patients.

2. Case
A 69-year-old woman presented to the Centre of Dermatovenereology (day 0) with purple bluish coloured nodules on her right hand, which slowly enlarged and ruptured into an ulcer. The patient had a significant past medical history of long standing renal failure and hemodialysis for 18 months therefore she became cadaveric renal transplant recipient (day −793). Her immunosuppression regimen consisted of systemic tacrolimus 2 mg/day, mycophenolate mofetil 360 mg/BD and methylprednisolone 4 mg/day (day −792 to day 0). The general condition of the patient was stable, laboratory tests within the normal range. On the 7th month of immunosuppression the woman noticed skin lesions on her hand but she did not take medical advice at that time. (day −583).

Examination revealed an erythemic ulcerated nodule on her right hand. Dermoscopy showed arborising vessels and Basal Cell Carcinoma (BCC) was suspected (day 0). Skin biopsy with Periodic acid-Schiff (PAS) staining presented epidermal and hair follicle epithelium proliferation and chronic inflammatory infiltration with possible infection of Cryptococcus spp. because of crypto-like insertions (day 7) (Fig. 1).

Cultures were not performed as specification of the Cryptococcus would not result in a different management approach. Initial treatment with oral fluconazole 200 mg/day for 10 days followed by 150 mg/day for 8 weeks was prescribed (day 7). Unfortunately, the patient discontinued the treatment and did not show up for further follow-ups as planned.

Nineteen months later the patient returned to the Dermatovenereology department (day +579). The previous purple bluish coloured nodule on her right hand grew up to 2 cm and was surrounded by erythema with central ulceration and liquid exudation. Additional lesions were found on patients’ right forearm and left cheek (Fig. 2 A,F).

Urine and blood analysis showed normal results, but exudate from the lesion serology examination showed colonization with Curvularia spp., (day +586). The fungus common in soil was an unexpected finding, but the patient admitted working in the garden recently. This secondary infection did not require additional treatment. The second histological examination of the skin lesion presented granulomatous inflammation with most possible infection – Cryptococcus spp. (day +594). Findings were comparable to first skin biopsy - crypto-like insertions and latent inflammatory infiltration.

Treatment of systemic itraconazole 200 mg/day and topical ketoconazole washing liquid 2–3 times/week, isononazole-diflucortolone cream 2 times/day and clotrimazole cream 2 times/day was prescribed.

https://doi.org/10.1016/j.mmcr.2020.03.004
Received 4 February 2020; Received in revised form 18 March 2020; Accepted 20 March 2020
Available online 31 March 2020

© 2020 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Targeted systemic and topical therapy resulted in a good clinical response. Repeated liver enzymes analysis showed normal liver function. Occurrence of fungal spores and affection of the lungs. In immunocompetent host, the infection is followed by hematogenous dissemination to central nervous system (CNS) and other organs as bones, joints or skin [1,3]. Cryptococcosis cutaneous manifestation is mostly a sign of dissemination [4]. Although, our patient had only cutaneous lesions with no marks of internal distribution.

Following candidiasis and aspergillosis, cryptococcosis is one of the most frequent fungal infections in solid-organ transplant recipients [5]. Occurrence is often seen around the 6th month post-transplant [6]. Our case was classical, as the patient presented with cryptococcal lesions in the 7th month post-transplant.

Cutaneous presentation of cryptococcosis is polymorphous, mostly manifesting as papules, pustules, nodules, abscesses, edema, panniculitis, ulcers, cellulitis or molluscum contagiosum alike lesions [7]. Organ transplant patients may also present necrotizing fasciitis, ecchymosis, eschar, purpura, cellulitis combined with necrotizing vasculitis, pyoderma gangrenosum like lesions or purple bluish coloured plaques [2] as in the reported case. Nonspecific clinical versions can mislead to other cutaneous conditions and cause serious diagnostic difficulties.

Skin biopsy combined with Romanowsky-type staining is the diagnostic test of choice for confirmation of cutaneous cryptococcosis. Although, Periodic acid-Schiff (PAS) staining can also be used as in our case. The yeasts are surrounded by clear halos that reflect the capsule, called crypto-like insertions [8].

Targeted treatment for cryptococcosis is referred in guidelines for the management of cryptococcal disease by the Infectious Diseases Society of America (IDSA) [9]. The management varies based on disease severity, organ involvement and patients’ immunological status. Treatment principles for cutaneous manifestations are the same caused by Cryptococcus gatti or Cryptococcus neoformans. In immunosuppressed patients non-CNS disseminated primary cutaneous cryptococcosis is treated with oral fluconazole 200–400 mg/day for 3–6 months or itraconazole 200–400 mg/day for 6–12 months followed by lifelong maintenance if required. Gradual reduction of immunosuppression is also recommended. In our case the antifungal treatment was started with fluconazole and later prolonged with itraconazole combined with topical medications. Lesions like this usually have an inflammatory component. Some studies show, that the addition of a topical corticosteroid to the antifungal therapy increases the bioavailability and prolongs the activity of the antifungal, while rapidly reducing inflammatory symptoms. The patient revealed good clinical response to the treatment and cryptococcosis was successfully managed.

3. Discussion

Cryptococcus spp. (most often neoformans) is an encapsulated opportunistic yeast found widely in the environment and associated with bird faeces, soil, plants, dust and infected food. Cryptococcosis may affect immunocompetent person, but typical host is under immunosuppression [1]. Prevalence of cryptococcal infection in solid-organ transplant recipients is 2–8%. Renal transplant recipients conclude the majority of cases [2]. Most patients present with pulmonary or central nervous system (CNS) infection and only 10–15% of patients with cryptococcosis develop cutaneous lesions [3].

Usually, as primary infection, cryptococcosis starts with inhalation of fungal spores and affection of the lungs. In immunocompetent host the patient is easily managed causing only transitory pulmonary symptoms. In immunocompromised host, the infection is followed by hematogenous dissemination to central nervous system (CNS) and other organs as bones, joints or skin [1,3]. Cryptococcosis cutaneous manifestation is mostly a sign of dissemination [4]. Although, our patient had only cutaneous lesions with no marks of internal distribution.

Following candidiasis and aspergillosis, cryptococcosis is one of the most frequent fungal infections in solid-organ transplant recipients [5]. Occurrence is often seen around the 6th month post-transplant [6]. Our case was classical, as the patient presented with cryptococcal lesions in the 7th month post-transplant.

Cutaneous presentation of cryptococcosis is polymorphous, mostly manifesting as papules, pustules, nodules, abscesses, edema, panniculitis, ulcers, cellulitis or molluscum contagiosum alike lesions [7]. Organ transplant patients may also present necrotizing fasciitis, ecchymosis, eschar, purpura, cellulitis combined with necrotizing vasculitis, pyoderma gangrenosum like lesions or purple bluish coloured plaques [2] as in the reported case. Nonspecific clinical versions can mislead to other cutaneous conditions and cause serious diagnostic difficulties.

Skin biopsy combined with Romanowsky-type staining is the diagnostic test of choice for confirmation of cutaneous cryptococcosis. Although, Periodic acid-Schiff (PAS) staining can also be used as in our case. The yeasts are surrounded by clear halos that reflect the capsule, called crypto-like insertions [8].

Targeted treatment for cryptococcosis is referred in guidelines for the management of cryptococcal disease by the Infectious Diseases Society of America (IDSA) [9]. The management varies based on disease severity, organ involvement and patients’ immunological status. Treatment principles for cutaneous manifestations are the same caused by Cryptococcus gatti or Cryptococcus neoformans. In immunosuppressed patients non-CNS disseminated primary cutaneous cryptococcosis is treated with oral fluconazole 200–400 mg/day for 3–6 months or itraconazole 200–400 mg/day for 6–12 months followed by lifelong maintenance if required. Gradual reduction of immunosuppression is also recommended. In our case the antifungal treatment was started with fluconazole and later prolonged with itraconazole combined with topical medications. Lesions like this usually have an inflammatory component. Some studies show, that the addition of a topical corticosteroid to the antifungal therapy increases the bioavailability and prolongs the activity of the antifungal, while rapidly reducing inflammatory symptoms. The patient revealed good clinical response to the treatment and cryptococcosis was successfully managed.
In conclusion, we would like to highlight the possibility of opportunistic pathogens such as Cryptococcus spp. in solid-organ transplant recipients. Only high attentiveness to cutaneous changes and appropriate treatment can lead to successful recovery from cryptococcosis in immunosuppressed transplant patients.

Declaration of competing interest

The authors declare there was no conflict of interests.

Acknowledgements

There is no acknowledgement the authors would like to declare.

References

[1] Y. Zhao, J. Lin, Y. Fan, X. Lin, Life cycle of cryptococcus neoformans, Annu. Rev. Microbiol. 73 (2019) 17–42, https://doi.org/10.1146/annurev-micro-020518-120210.
[2] I. Gassiep, D. McDougall, J. Douglas, R. Francis, E.G. Playford, Cryptococcal infections in solid organ transplant recipients over a 15-year period at a state transplant center, Transpl. Infect. Dis. 19 (1) (2017) e12639, https://doi.org/10.1111/tid.12639.
[3] M.Z. Hayashida, C.A. Seque, V.P. Pasin, S. Enokihara MMS e, A.M. Porro, Disseminated cryptococcosis with skin lesions: report of a case series, An. Bras. Dermatol. 92 (5 suppl 1) (2017) 69–72, https://doi.org/10.1590/abd1806-4841.20176343.
[4] G.N. Srivastava, R. Tilak, J. Yadav, M. Bansal, Cutaneous Cryptococcus: marker for disseminated infection, BMJ Case Rep. (2015), https://doi.org/10.1136/bcr-2015-210898.bcr2015210898.
[5] J. Gavaldà, Y. Meije, J. Fortún, E. Roilides, F. Saliba, O. Lortholary, et al., Invasive fungal infections in solid organ transplant recipients, Clin. Microbiol. Infect. 20 (2014) 27–48, https://doi.org/10.1111/cmi.12228.
[6] S. Marques, R. Carmo, I. Ferreira, M. Bustorff, S. Sampaio, M. Pestana, Cryptococcosis in renal transplant recipients: a single-center experience, Transplant. Proc. 48 (7) (2016) 2289–2293, https://doi.org/10.1016/j.transproceed.2016.06.006.
[7] L. Du, Y. Yang, J. Gu, J. Chen, W. Liao, Y. Zhu, Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients, Mycopathologia 180 (1–2) (2015) 19–25, https://doi.org/10.1007/s11046-015-9880-7.
[8] R. Marcos, F. Malhão, J. Santos, S. Marques, G. Thompson, M. Santos, The cryptic Cryptococcus, Vet. Clin. Pathol. 45 (4) (2016) 532–533, https://doi.org/10.1111/vcp.12421.
[9] J.R. Perfect, W.E. Dismukes, F. Dromer, D.L. Goldman, J.R. Graybill, R.J. Hamill, et al., Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America, Clin. Infect. Dis. 50 (3) (2010) 291–322, https://doi.org/10.1086/649858.